Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Bullboard Posts
Post by rome1on Dec 20, 2012 10:36am
333 Views
Post# 20755421

Too Bad

Too Bad

Well, after having my head handed to me by V.SSS a few years ago ...I swore I would never ride another FDA /  phase result on a junior biotech...I  will only buy and hold but always sell before the results are finally released.

In the one in a million chance it is a blockbuster ...I am willing to buy back in at a higher price.

Next on the radar....SDI...also in a phase III and will surely enjoy a ride up over the next months / year.

Good luck to whom ever looks at this stock...

As for NPC it is likely over....a reverse split is likely the only option to raise capital in the future. 1 for 10 or something like that...followed by the usual financings and the years (5-10) to see another set of trials from start to finish.

That junior biotechs for you.

 

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse